Takis disposes of a large collection (>100) of human and murine cancer cell lines. We can analyze the effects of drugs and the connected molecular events. Cells can also be engineered to knock-down a target of interest and evaluate its biological role.

  • Our services include:
  • In vitro evaluation of citotoxicity and cell proliferation
  • In vitro migration and differentiation assays
  • Clonogenic assays
  • Apoptosis and cell cycle assays
  • Foci forming gH2AX, Rad51, BRCA1 assays
  • PARP1 inhibition assays
  • HDAC inhibition assays
  • Immunohistochemistry of tumor samples



Tumor initiating cells from lung adenocarcinoma pleural effusions

In close collaboration with Dept. of Clinical and Experimental Medicine, Laboratory of Surgery, University of Rome La Sapienza, we have set up and optimized methods to isolate Tumor Initiating Cells (TICs) from primary tumors: an exceptional tool for personalized medicine and to test novel drugs and combination therapies.

Malignant pleural effusion 650


overrexpressing stem cell markers 650


 tumorigenicity in vivo 650


Drug Testing on TICs

If you want to assess the efficacy on cancer cells with stem potential, Takis offer the Drug testing services on Tumor Initiating Cells

  • Access to freshly explanted human tumor samples
  • Standardized protocol for isolation of TICs from Lung, Colon, Melanoma Cancer
  • Characterization by mutation status (e.g. p53, EGFR), receptor expression (e.g. HER family, Met) and pathway activation (e.g. MAPK, Akt)
  • Combo treatments (e.g. mAbs and chemotherapy)

untread drugx 650

untread drugx graph 650


Follow Us on Linkedin

Takis is a biotech dedicated to cancer research. Our primary objective is the development of innovative therapies based on the principle that our immune system can be “instructed” to recognize the tumor and reject it as a foreign entity.